alea-institute/kl3m-data-sample-004-shuffled huggingface dataset:
§ 520.38b Albendazole paste. ( a ) *Specifications.* The product contains 30 percent albendazole.
( b ) *Sponsor.* See No. 054771 in § 510.600(c) of this chapter.
( c ) *Related tolerances.* See § 556.34 of this chapter.
( d ) *Conditions of use in cattle* — ( 1 ) *Amount.* Equivalent to 4.54 milligrams per 1 pound of body weight (10 milligrams per kilogram).
( 2 ) *Indications for use.* For removal and control of the following internal parasites of cattle: adult liver flukes (*Fasciola hepatica*); heads and segments of tapeworms (*Moniezia benedeni, M. expansa*); adult and 4th stage larvae of stomach worms (brown stomach worms including 4th stage inhibited larvae (*Ostertagia ostertagi*); barberpole worm (*Haemonchus contortus, H. placei*); small stomach worm (*Trichostrongylus axei*)); adult and 4th stages larvae of intestinal worms (thread-necked intestinal worm (*Nematodirus spathiger, N. helvetianus*); small intestinal worm (*Cooperia punctata* and *C. oncophora*)); adult stages of intestinal worms (hookworm (*Bunostomum phlebotmum*); bankrupt worm (*Trichostrongylus colubriformis*), nodular worm (*Oesophagostomum radiatum*)); adult and 4th stage larvae of lungworms (*Dictyocaulus viviparus*).
( 3 ) *Limitations.* Administer as a single oral dose. Do not slaughter within 27 days of last treatment. Do not use in female dairy cattle of breeding age. Do not administer to female cattle during first 45 days of pregnancy or for 45 days after removal of bulls. Consult your veterinarian for assistance in the diagnosis, treatment, and control of parasitism.
[54 FR 51385, Dec. 15, 1989, as amended at 56 FR 50653, Oct. 8, 1991; 60 FR 55658, Nov. 2, 1995. Redesignated at 78 FR 66264, Nov. 5, 2013, as amended at 79 FR 28816, May 20, 2014]
EXHIBIT 11
<TABLE>
<CAPTION>

                           COMMODORE HOLDINGS LIMITED
               COMPUTATION OF EARNINGS PER SHARE OF COMMON STOCK

                                                                                 PERIOD FROM
                                                                                APRIL 13, 1995
                                                                             (DATE OF INCEPTION)
                                             YEAR ENDED        YEAR ENDED         THROUGH
                                            SEPTEMBER 30,     SEPTEMBER 30,     SEPTEMBER 30,   
COMPUTATION FOR STATEMENT OF OPERATIONS        1997               1996             1995
---------------------------------------     -------------     -------------  -------------------
<S>                                         <C>               <C>            <C>                
Primary earnings per share
  Net earnings                              $2,003,254        $1,729,482     $  251,535

Reduction of interest expense for
  presumed repayment of debt 
  (as determined by the application
  of the modified treasury stock method)            --           124,279             --
                                            ----------        ----------     ----------

Adjusted net earnings                       $2,003,254        $1,853,761     $  251,535
                                            ==========        ==========     ==========

Shares

  Weighted average number of
    common shares outstanding                5,581,933         5,055,977      4,124,815

Add: Dilutive effect to options and
  warrants (as determined by the
  application of the treasury stock
  method for the year ended
  September 30, 1997 and the period
  ended September 30, 1995 and the
  modified treasury stock method for
  the year ended September 30, 1996)           219,822           383,613        252,778
                                            ----------        ----------     ----------

Weighted average common and
  common equivalent shares                   5,801,755         5,439,590      4,377,593
                                            ==========        ==========     ==========

Earnings (loss) per common and
  common equivalent shares                  $     0.35        $     0.34     $     0.06
                                            ==========        ==========     ==========

Fully diluted earnings (loss)    
  per share
    Net earnings (loss) as per
      primary calculation above             $     0.35        $     0.34     $     0.06
                                            ==========        ==========     ==========

</TABLE>
<PAGE>   1
    Exhibit
      No.             Title
    -------           -----

      11              COMPUTATION OF PER SHARE EARNINGS


                           National Datacomputer, Inc.
        Statement Re: Computation of net income (loss) per common share


<TABLE>
<CAPTION>
                                                 September 30,     September 28,
                                                     1998              1997
                                                 -------------     -------------
<S>                                               <C>               <C>         
Net loss, as reported                             $  (234,619)      $(1,026,157)

Preferred stock preference items:

     Discount inherent in conversion
     terms of Series C and D convertible
     preferred stock upon issuance                    (46,602)             --

      Warrant                                        (214,000)             --

     Interest on Series B, C and D
     convertible preferred stock                     (308,250)         (302,000) 
                                                  -----------       ----------- 

Total preferred stock preference item                (568,852)         (302,000)

Net loss attributable to common
stockholders                                      $  (803,471)      $(1,328,157)
                                                  -----------       ----------- 

Weighted average shares outstanding                 1,801,876         1,277,157
                                                  ===========       =========== 

Net loss  per share                               $     (0.45)      $     (1.04)
                                                  ===========       =========== 
</TABLE>


Note: Due to the Company's net loss, no exercises of options or conversions of
      preferred stock have been assumed, because all such items would be
      anti-dilutive.


                                       15
§ 522.1884 Prednisolone sodium succinate. ( a ) *Specifications.* Each milliliter of prednisolone sodium succinate injection contains: Prednisolone sodium succinate equivalent in activity to 10, 20, or 50 milligrams (mg) of prednisolone.
( b ) *Sponsor.* See No. 054771 in § 510.600(c) of this chapter for products containing 10, 20, and 50 mg equivalent prednisolone activity per milliliter for use in horses, dogs, and cats as provided in paragraphs (c)(1)(i), (ii), and (iii) of this section.
( c ) *Conditions of use* — ( 1 ) *Amount and indications for use* — ( i ) *Horses.* Administer 50 to 100 mg as an initial dose by intravenous injection over a period of one-half to 1 minute, or by intramuscular injection, and may be repeated in inflammatory, allergic, or other stress conditions at intervals of 12, 24, or 48 hours, depending upon the size of the animal, the severity of the condition and the response to treatment.
( ii ) *Dogs.* Administer by intravenous injection at a range of 2.5 to 5 mg per pound of body weight as an initial dose followed by maintenance doses at 1, 3, 6, or 10 hour intervals, as determined by the condition of the animal, for treatment of shock.
( iii ) *Dogs and cats.* Administer by intramuscular injection for treatment of inflammatory, allergic, and less severe stress conditions, where immediate effect is not required, at 1 to 5 mg ranging upward to 30 to 50 mg in large breeds of dogs. Dosage may be repeated in 12 to 24 hours and continued for 3 to 5 days if necessary. If permanent corticosteroid effect is required, oral therapy with prednisolone tablets may be substituted.
( 2 ) *Limitations.* Do not use in horses intended for human consumption. Federal law restricts this drug to use by or on the order of a licensed veterinarian.
[79 FR 16194, Mar. 25, 2014]
* Pursuant to 5TH CIR. R. 47.5, the court has determined that

this opinion should not be published and is not precedent except

under the limited circumstances set forth in 5TH CIR. R. 47.5.4.

United States Court of Appeals

Fifth Circuit

FILED

December 17, 2004

Charles R. Fulbruge III

Clerk

IN THE UNITED STATES COURT OF APPEALS

FOR THE FIFTH CIRCUIT

 

No. 04-50642

Conference Calendar

 

UNITED STATES OF AMERICA,

Plaintiff-Appellee,

versus

TOMMY LEE CATHEY,

Defendant-Appellant.

--------------------

Appeal from the United States District Court

for the Western District of Texas

USDC No. 1:03-CR-230-ALL-SS

--------------------

Before KING, Chief Judge, and DeMOSS and CLEMENT, Circuit Judges.

PER CURIAM:*

Appealing the Judgment in a Criminal Case, Tommy Lee Cathey

raises arguments that are foreclosed by United States v. Pineiro,

377 F.3d 464, 465-66 (5th Cir. 2004), petition for cert. filed

(U.S. July 14, 2004) (No. 04-5263), which held that Blakely v.

Washington, 124 S. Ct. 2531 (2004), does not apply to the United

States Sentencing Guidelines. The Government’s motion for

summary affirmance is GRANTED, and the judgment of the district

court is AFFIRMED.
**Exhibit 23.1**

 

Consent ofStegman and Company

 

----

 

 

**CONSENTOF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM**

 

Boardof Directors and StockholdersFirst Mariner BancorpBaltimore, Maryland

 

Weconsent to the incorporation by references in the Registration Statements (Nos.333-60961, 333-60963, 333-60967, 333-107669, 333-114073 and 333-122464) onForm S-8 (No. 333-107670) on Form S-3 and (No. 333-67854)on Form S-2 of First Mariner Bancorp (the “Company”) of our report dated February 20,2005, relating to the consolidated statements of financial condition of theCompany as of December 31, 2004 and 2003, and the related consolidatedstatements of operations, changes in stockholders’ equity and cash flows foreach of the three years in the period ended December 31, 2004, whichreport appears in the December 31, 2004 annual report on Form 10-K ofthe Company.

 
|                | /s/ Stegman & Company |   |
|---------------------|---------------------------|--------|
|                |                      |
| Baltimore, Maryland |                      |
| March 14, 2005 |                      |

 

----
Exhibit 23.1

                       [Letterhead of DeAngelis & Higgins]

The Board of Directors
WorldWater Corp.
Pennington Business Park
55 Route 31 South
Pennington, New Jersey 08534

We consent to the use of our report included in the Annual Report on Form 10-KSB
for the year ended December 31, 1998 incorporated herein by reference.


                                               /s/ DeAngelis & Higgins, L.L.C.
                                               -------------------------------
                                               DeAngelis & Higgins, L.L.C.
Cranbury, New Jersey
January 18, 2000
Document Headings

                    Document headings vary by document type but may contain                    the following:                  
                -                       the agency or agencies that issued and signed a document                    
                -                       the number of the CFR title and the number of each part                      the document amends, proposes to amend, or is directly                      related to                    
                -                       the agency docket number / agency internal file number                    
                -                       the RIN which identifies each regulatory action listed in                      the Unified Agenda of Federal Regulatory and Deregulatory                      Actions                    

                    See the                                          Document Drafting Handbook                                        for more details.                  

###### Department of Agriculture

###### Forest Service

# AGENCY:

Forest Service, USDA.

# ACTION:

Notice of Meeting.

# SUMMARY:

The Tehama County Resource Advisory Committee (RAC) will meet in Red Bluff, California. Agenda items to be covered include: (1) Introductions, (2) Approval of Minutes, (3) Public Comment, (4) Chairman's Perspective, (5) Elect Vice Chairmen, (6) Next Agenda.

# DATES:

The meeting will be held on March 25, 2010 from 9 a.m. and end at approximately 12 p.m.

# ADDRESSES:

The meeting will be held at the Lincoln Street School, Pine Room, 1135 Lincoln Street, Red Bluff, CA. Individuals wishing to speak or propose agenda items must send their names and proposals to Randy Jero, Committee Coordinator, 825 N. Humboldt Ave., Willows, CA 95988.

# FOR FURTHER INFORMATION CONTACT:

                        Randy Jero, Committee Coordinator, USDA, Mendocino National Forest, Grindstone Ranger District, 825 N. Humboldt Ave, Willows, CA 95988. (530) 934-1269; e-mail                         *rjero@fs.fed.us.*

# SUPPLEMENTARY INFORMATION:

The meeting is open to the public. Committee discussion is limited to Forest Service staff and Committee members. However, persons who wish to bring matters to the attention of the Committee may file written statements with the Committee staff before or after the meeting. Public input sessions will be provided and individuals who made written requests by March 22, 2010 will have the opportunity to address the committee at those sessions.

Eduardo Olmedo,

Designated Federal Official.

[FR Doc. 2010-4320 Filed 3-2-10; 8:45 am]

BILLING CODE 3410-11-M
Exhibit 32.1
                                                                  ------------
         Section 1350 Certifications of Principal Executive Officer and
                           Principal Financial Officer
            Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002

         Pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906
of the Sarbanes-Oxley Act of 2002, the undersigned officers of 1st Independence
Financial Group, Inc. (the "Company"), hereby certify, to such officer's
knowledge, that:

         The Annual Report on Form 10-KSB for the year ended December 31,
2005 (the  "Report") of the Company  fully  complies  with the  requirements  of
section  13(a)  or  15(d)  of the  Securities  Exchange  Act  of  1934  and  the
information  contained in the Report fairly presents,  in all material respects,
the financial condition and results of operations of the Company.



Dated: March 16, 2006       /s/ N. William White
                                --------------------------------
                                Name:     N. William White
                                Title:    President and Chief Executive Officer
                                          (Principal Executive Officer)


                            /s/ R. Michael Wilbourn
                                --------------------------------
                                Name:     R. Michael Wilbourn
                                Title:    Executive Vice President
                                          and Chief Financial Officer
                                          (Principal Financial Officer)
Participants on call with AAPCA Member states

Held 11/30/2015

AAPCA

Clint Woods, AAPCA

AAPCA Member State Participants

Alabama

Arkansas

Florida

Kentucky

Louisiana 

North Carolina 

North Dakota

Ohio 

Tennessee 

Texas

West Virginia 

Wyoming 

EPA Participants

Bruce Moore, OAQPS

Chris Stoneman, OAQPS

Cheryl Vetter, OAQPS

Jodi Howard, OAQPS

Gerri Garwood, OAQPS

Lisa Thompson, OAQPS

Charlene Spells, OAQPS

Jameel Alsalam, OAP

Jackie Ashley, OAQPS
Matt Witosky, OAQPS

ECR ? 

Greg Nizich, OAQPS

Amy Hambrick, OAQPS
EXHIBIT 32.2
 
 
 CERTIFICATION OF CHIEF FINANCIAL OFFICER PURSUANT TO
 18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT TO SECTION 906
 OF THE SARBANES-OXLEY ACT OF 2002
 
 
 This certification is provided pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 and accompanies the Quarterly Report on Form 10-Q (the “Form 10-Q”) for the quarter ended March 31, 2010 of Crimson Exploration Inc. (the “Issuer”).  The undersigned hereby certifies that the Form 10-Q fully complies with the requirements of Section 13(a) or Section 15(d) of the Securities Exchange Act of 1934 (15 U.S.C. 78m or 78o(d)) and that the information contained in the Form 10-Q fairly presents, in all material respects, the financial condition and results of operations of the Issuer.
 
 Date:
May 11, 2010/s/ E. Joseph GradyName:
E. Joseph GradyTitle:
Senior Vice President andChief Financial Officer
 
 
 A signed original of this written statement required by Section 906 has been provided to the Issuer and will be furnished to the Securities and Exchange Commission, or its staff, upon request.
38794.

#### GENERAL OGLETHORPE HOTEL COMPANY v. WOODS.

Carlisle, Presiding Judge.

Woods sued the General Oglethorpe Hotel Co. for an amount alleged to be due him on an open account for gratuities collected by the defendant on his behalf while he was employed as defendant’s catering manager. The defendant, by its answer as amended, admitted an indebtedness to the plaintiff in a lesser amount. Upon the trial of the case, the court permitted the plaintiff to introduce a portion of a letter admittedly written by the defendant’s auditor to the plaintiff, as follows: “That s.o.b. says he will be here within the next day or so, and we will get at your tips! I hope that I can make him pay up.” The objections to' this were that the letter was a personal communication between the auditor and the plaintiff; that there was no evidence to- show that it was authorized by the defendant corporation; that it was introduced for the purpose of influencing the minds of the jury because of its intemperate language; that it was highly prejudicial; that it contained slander and that it was irrelevant and immaterial. The admission of this letter is assigned as error in special ground 1 of the motion for a new trial, and the failure of the court to exclude the intemperate portions is assigned as error in ground 2, and the failure to grant a mistrial on account of the admission of this letter is assigned as error in special ground 3. All of these grounds present substantially the same question.

While it is true that there was no evidence introduced to show that the letter was authorized by the defendant corporation and, consequently, it was not admissible under *Code*§ 4-315 *623*(East Tenn. &c. Ry. Co. v. Johnson & Shahan,*85 Ga. 497 (3), 11 S. E. 809; *Cable Co. v. Parantha,*118 Ga. 913 (2), 45 S. E. 787; *Bazemore v. MacDougald Constr. Co.,*85 Ga. App. 107 (2), 68 S. E. 2d 163; *Atlantic Coast Line R. Co. v. Marshall,*93 Ga. App. 134, 137 (8), 91 S. E. 2d 96), the harmful effect of such evidence, if any, insofar as the defendant is concerned, could have been no more than to admit some- indebtedness to the plaintiff. But this had already been admitted by the defendant in its pleadings and by the defendant’s witnesses on direct and cross-examination.' • There was no objection that such letter was hearsay, and the mere fact that it was a personal communication between the auditor and the plaintiff or that it was introduced for the purpose of influencing the minds of the jury by its intemperate language, did not per se render it inadmissible. The other grounds of objection were entirely too- general to present any question for decision. The admission of this evidence over the objections urged was not harmful error, and the trial court did not err in overruling the.three special grounds of the motion for a new trial.

Decided April 25, 1961

Rehearing denied May 8,1961.

*Aaron Kravitch,*for plaintiff in error.

*Bobert E. Falligant,*contra.

*Judgment affirmed.*

*Nichols and Eberhardt, JJ.', concur-*
§ 820.13 Direction to NNSA contractors. ( a ) Notwithstanding any other provision of this part, and pursuant to section 3213 of Pub. L. 106-65, as amended (codified at 50 U.S.C. 2403), the NNSA, rather than the Director, signs, issues and serves the following actions that direct NNSA contractors: ( 1 ) Subpoenas;
( 2 ) Orders to compel attendance;
( 3 ) Disclosures of information or documents obtained during an investigation or inspection;
( 4 ) Preliminary notices of violations; and
( 5 ) Final notices of violations.
( b ) The NNSA Administrator shall act after consideration of the Director's recommendation.
[72 FR 31921, June 8, 2007]
§ 520.2090 Sarolaner, moxidectin, and pyrantel. ( a ) *Specifications.* Each chewable tablet contains: ( 1 ) 3.0 mg sarolaner, 0.06 mg moxidectin, and 12.5 milligrams (mg) pyrantel (as pamoate salt);
( 2 ) 6.0 mg sarolaner, 0.12 mg moxidectin, and 25.0 mg pyrantel (as pamoate salt);
( 3 ) 12.0 mg sarolaner, 0.24 mg moxidectin, and 50.0 mg pyrantel (as pamoate salt);
( 4 ) 24.0 mg sarolaner, 0.48 mg moxidectin, and 100 mg pyrantel (as pamoate salt);
( 5 ) 48.0 mg sarolaner, 0.96 mg moxidectin, and 200 mg pyrantel (as pamoate salt); or
( 6 ) 72.0 mg sarolaner, 1.44 mg moxidectin, and 300 mg pyrantel (as pamoate salt).
( b ) *Sponsor.* See No. 054771 in § 510.600(c) of this chapter.
( c ) *Conditions of use in dogs* — ( 1 ) *Amount.* Administer orally, once a month, at the recommended minimum dose of 0.54 mg/lb (1.2 mg/kg) sarolaner, 0.011 mg/lb (24 μg/kg) moxidectin, and 2.27 mg/lb (5 mg/kg) pyrantel (as pamoate salt).
( 2 ) *Indications for use.* For the prevention of heartworm disease caused by *Dirofilaria immitis* and for the treatment and control of roundworm (immature adult and adult *Toxocara canis* and adult *Toxascaris leonina*) and hookworm (L4, immature adult, and adult *Ancylostoma caninum* and adult *Uncinaria stenocephala*) infections. Kills adult fleas (*Ctenocephalides felis*) and is indicated for the treatment and prevention of flea infestations, and the treatment and control of tick infestations with *Amblyomma americanum* (lone star tick), *Amblyomma maculatum* (Gulf Coast tick), *Dermacentor variabilis* (American dog tick), *Ixodes scapularis* (black-legged tick), and *Rhipicephalus sanguineus* (brown dog tick) for 1 month in dogs and puppies 8 weeks of age and older, and weighing 2.8 pounds or greater. For the prevention of *Borrelia burgdorferi* infections as a direct result of killing *Ixodes scapularis* vector ticks.
( 3 ) *Limitations.* Federal law restricts this drug to use by or on the order of a licensed veterinarian.
[85 FR 45307, July 28, 2020, as amended at 86 FR 57997, Oct. 20, 2021; 87 FR 17945, Mar. 29, 2022]